TY - JOUR T1 - The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 641 LP - 655 DO - 10.1097/IGC.0000000000001216 VL - 28 IS - 4 AU - David Cibula AU - Richard Pötter AU - François Planchamp AU - Elisabeth Avall-Lundqvist AU - Daniela Fischerova AU - Christine Haie Meder AU - Christhardt Köhler AU - Fabio Landoni AU - Sigurd Lax AU - Jacob Christian Lindegaard AU - Umesh Mahantshetty AU - Patrice Mathevet AU - W. Glenn McCluggage AU - Mary McCormack AU - Raj Naik AU - Remi Nout AU - Sandro Pignata AU - Jordi Ponce AU - Denis Querleu AU - Francesco Raspagliesi AU - Alexandros Rodolakis AU - Karl Tamussino AU - Pauline Wimberger AU - Maria Rosaria Raspollini Y1 - 2018/05/01 UR - http://ijgc.bmj.com/content/28/4/641.abstract N2 - Background Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer.Objective The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.Methods The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.Results The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined. ER -